On Tuesday, BioNTech ADR earned an upgrade to its Relative Strength (RS) Rating, from 78 to 82.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
BioNTech ADR is working on a consolidation with a 131.49 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
BioNTech ADR saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 29%. Revenue rose from -25% to 46%.
BioNTech ADR holds the No. 109 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
